Quotables
"During my service in the United States Congress, I took the initiative in creating the Internet."
Al Gore ; The basis for the later misquote by US Republicans that Gore had "invented" the Internet. Gore was the leading political champion of the modern-day Internet.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8173621 | Nucleoside cyclicphosphates Cyclic phosphate of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof, represented by the following structure: | 05/08/2012 |
| 8063025 | Nucleoside prodrugs and uses thereof Compounds having the formula I or II wherein R1, R2, B, and V are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication. ... | 11/22/2011 |
| 7666855 | 2′-C-methyl nucleoside derivatives Compounds of Formula I, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described: ... | 02/23/2010 |
| 7439349 | Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary uses thereof Method for producing large lots of final sterile Poly-ICLC suitable for clinical use with reduced toxicity at effective dose levels, and method for using Poly-ICLC to regulate genes, and method for using Poly-ICLC to treat certain human and veterinary infectious, ne... | 10/21/2008 |
| 7435724 | Degradation-resistant mononucleoside phosphate compounds The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on ... | 10/14/2008 |
| 7429569 | Compositions and methods for the regulation of homocysteine levels within the body Described herein is a method for reducing levels of the harmful metabolic waste product of S-adenosylmethionine (SAMe), homocysteine, and provide vitamin and other nutritional co-factors that reduce the production of homocysteine and either re-methylate homocysteine... | 09/30/2008 |
| 7429571 | Therapeutic furopyrimidines and thienopyrimidines The invention provides compounds of formula I, II, and III as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of formula I, II, and ... | 09/30/2008 |
| 7429570 | Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes ... | 09/30/2008 |
| 7425546 | Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes ... | 09/16/2008 |
| 7407944 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of... | 08/05/2008 |
| 7399754 | N-quinoline or isoquinoline substituted purine derivatives Novel compound having the following formula: wherein W represents a hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C3-6 cycloalkyl, or an optionally substituted C1-6 | 07/15/2008 |
| 7396825 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy The present invention provides a therapeutic method for treating diabetic kidney disease, e.g., diabetic nephropathy that includes the administration of an effective amount of an A2A adenosine receptor agonist. Optionally, the method includes administrati... | 07/08/2008 |
| 7371852 | Alkyl-linked nucleotide compositions Alkyl-linked nucleotide non-homogeneous solid supports and nucleotide affinity media comprising an alkyl-linked nucleotide are provided. The linker is generally a hydrophobic linker that can be a 3, 4, 5, 6, 7, 8, 9, 10, or a longer carbon chain. Also included in th... | 05/13/2008 |
| 7354907 | Short immunomodulatory oligonucleotides The invention relates to modulation of the immune system. More particularly, the invention relates to modulating the immune system through the use of oligonucleotide-derived compounds. The invention provides immunostimulatory agents that are less expensive to make t... | 04/08/2008 |
| 7326694 | Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes ... | 02/05/2008 |
| 7323453 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds The present invention provides methods of inhibiting orthopoxvirus replication and/or treating orthopoxvirus infection with certain nucleoside compounds and derivatives thereof. These compounds are particularly useful as inhibitors of vaccinia virus and variola viru... | 01/29/2008 |
| 7323452 | Method for the accelerated in vivo removal of ethanol A method for accelerating the process of removing ethanol from the blood through the use of certain additives that accelerate the metabolic oxidation of ethanol, and others which in addition act as catalysts or “pseudo” enzymes for the oxidation. These additives... | 01/29/2008 |
| 7321033 | 3-B-D-ribofuranosylthiazolo [4,5-] pyrimidine nucleosides and uses thereof The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compou... | 01/22/2008 |
| 7304043 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereo... | 12/04/2007 |
| 7294619 | Lipid analogs for inhibiting the activity of hepatitis B antigen The invention relates to methods of treating viral infections, and in particular hepatitis B virus. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative to inhibit the ... | 11/13/2007 |
| 7294621 | Lipid analogs for combating tumors The invention relates to methods of treating viral infections, and in particular hepatitis B virus. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative to inhibit the ... | 11/13/2007 |
| 7294620 | Lipid analogs for inhibiting HIV-1 activity The invention relates to methods of treating viral infections, and in particular hepatitis B virus. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative to inhibit the ... | 11/13/2007 |
| 7276489 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of... | 10/02/2007 |
| 7256183 | Method for treating or preventing inflammatory diseases The present invention provides a method of preventing or treating an inflammatory disease, including but not limited to, sinusitis, rhinitis, conjunctivitis, asthma, dermatitis, inflammatory bowel disease, inflammatory collagen vascular diseases, glomerulonephritis,... | 08/14/2007 |
| 7247621 | Antiviral phosphonate compounds and methods therefor Pharmaceutical compositions comprise a nucleotide analog with a phosphonate group at a concentration effective to act as a substrate and/or inhibitor of a viral polymerase, and especially of the HCV RNA dependent RNA polymerase. ... | 07/24/2007 |
| 7226913 | Pharmaceutical compositions having Aadenosine receptor agonist activity The present invention provides compositions for oral administration of compounds having A2A adenosine receptor agonist activity. These compositions are useful for treatment of inflammatory conditions. ... | 06/05/2007 |
| 7214665 | 2-propynyl adenosine analogs having Aagonist activity and compositions thereof The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described here. ... | 05/08/2007 |
| RE39573 | Antimutagenic compositions for treatment and prevention of photodamage to skin A method of improving DNA repair and reducing DNA damage and for reducing mutation frequency in skin for the purpose of reducing consequences of exposure to solar or ultraviolet radiation is disclosed. The methods comprise administering to the skin a composition con... | 04/17/2007 |
| RE39497 | Storage of materials A material or mixture of materials which is not itself storage stable is rendered storage stable by incorporation into a water-soluble or swellable glassy or rubbery composition which can then be stored at ambient temperature. Recovery is by adding aqueous solution ... | 02/27/2007 |
| 7176296 | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides The invention provides compounds having increased or reduced immunostimulatory effect, said compounds comprising a CpG dinucleotide and an immunomodulatory moiety wherein the increased or reduced immunomodulatory effect is relative to a similar compound lacking the ... | 02/13/2007 |
| 7169765 | Acyl deoxyribonucleoside derivatives and uses thereof The invention relates to compositions comprising acyl derivatives of 2′-deoxyribonucleosides. The invention also relates to methods of treating or preventing radiation, mutagen and sunlight-induced biological damage, and methods for improving wound healing and tis... | 01/30/2007 |
| 7157449 | Medicament for the treatment of diseases caused by parasitic protozoa The present invention relates to the use of an inhibitor of CTP synthetase, such as a glutamine analogue, and a substance capable of suppressing toxic effects thereof in vivo, in the manufacture of a medicament for the treatment of a disease caused by a parasitic pr... | 01/02/2007 |
| 7157441 | Methods and compositions for treating hepatitis C virus A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.... | 01/02/2007 |
| 7153840 | Aqueous fludarabine phosphate composition This invention is directed towards a ready-to-use aqueous composition of fludarabine phosphate. In one embodiment, the invention is directed to an aqueous fludarabine phosphate composition which comprises fludarabine phosphate, a base, and water. The concentration o... | 12/26/2006 |
| 7153877 | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bo... | 12/26/2006 |
| 7148207 | Oral fludara of high-purity formulation with quick release of active ingredient This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants. ... | 12/12/2006 |
| 7148206 | Methods and compositions for treating flaviviruses and pestiviruses A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug... | 12/12/2006 |
| 7132408 | Composition and method for inhibiting platelet aggregation This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject a pharmaceutical composition... | 11/07/2006 |
| 7132410 | Di(uridine 5′-)tetraphosphate and salts thereof The present invention are directed to P1, P4-di(uridine 5′-)tetraphosphate, tetra-alkali metal salts such as tetrasodium, tetralithium, tetrapotassium, and mixed tetra-alkali metal cations thereof. The tetra alkali metal salts of P1 | 11/07/2006 |
| 7119110 | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bo... | 10/10/2006 |
